PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) EVP Hisham Shiblaq sold 247 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $14,093.82. Following the transaction, the executive vice president now owns 63,133 shares of the company's stock, valued at approximately $3,602,368.98. The trade was a 0.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
PROCEPT BioRobotics Trading Up 0.4 %
Shares of NASDAQ:PRCT traded up $0.23 during mid-day trading on Friday, hitting $58.10. The company had a trading volume of 666,081 shares, compared to its average volume of 727,334. The firm has a fifty day moving average price of $67.15 and a 200 day moving average price of $78.34. The company has a market capitalization of $3.18 billion, a PE ratio of -29.79 and a beta of 1.05. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a one year low of $45.56 and a one year high of $103.81.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.
Analyst Ratings Changes
Several research analysts have issued reports on the stock. Wells Fargo & Company restated an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Truist Financial restated a "buy" rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.29.
Read Our Latest Stock Analysis on PRCT
Institutional Trading of PROCEPT BioRobotics
Several hedge funds have recently modified their holdings of the stock. Westfield Capital Management Co. LP bought a new stake in PROCEPT BioRobotics during the 3rd quarter valued at $72,563,000. FMR LLC increased its stake in PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Perpetual Ltd bought a new stake in PROCEPT BioRobotics during the 4th quarter valued at $66,972,000. Wellington Management Group LLP increased its stake in PROCEPT BioRobotics by 38.8% during the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock valued at $120,051,000 after purchasing an additional 416,819 shares in the last quarter. Finally, Franklin Resources Inc. increased its stake in PROCEPT BioRobotics by 64.5% during the 3rd quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock valued at $64,669,000 after purchasing an additional 347,330 shares in the last quarter. Institutional investors own 89.46% of the company's stock.
About PROCEPT BioRobotics
(
Get Free Report)
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
See Also
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
